# Safety

## Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data

**Background:** Dupilumab is the first biologic registered for the treatment of moderate-to-severe atopic dermatitis (AD) and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, …

## The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy

**Background**: After 5 years since the registration of rifaximin-$\alpha$ as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-$\alpha$ …